1,812 results on '"Vogelmeier Claus"'
Search Results
2. Midregional Proatrial Natriuretic Peptide (MRproANP) is associated with vertebral fractures and low bone density in patients with chronic obstructive pulmonary disease (COPD)
3. Effects of triple therapy on disease burden in patients of GOLD groups C and D: results from the observational COPD cohort COSYCONET
4. GOLD COPD DOCUMENT 2023: a brief update for practicing cardiologists
5. Genetisch bedingte Lungenerkrankungen
6. Nachruf auf Prof. Dr. med. Tobias Welte
7. Managing and discharging COPD patients hospitalized because of an exacerbation of respiratory symptoms: An opportunity to improve outcomes
8. Gold 2023: Highlights for primary care
9. In ‘real world’ patients with COPD, exacerbation history, and not blood eosinophils, is the most reliable predictor of future exacerbations
10. Chronic Airways Assessment Test: psychometric properties in patients with asthma and/or COPD
11. EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
12. A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”
13. Impact of COPD on mortality: An 8-year observational retrospective healthcare claims database cohort study
14. Potential systemic effects of acquired CFTR dysfunction in COPD
15. Digitalisierung in der Pneumologie
16. Gender-specific differences in COPD symptoms and their impact for the diagnosis of cardiac comorbidities
17. COPD and multimorbidity: recognising and addressing a syndemic occurrence
18. Krüppel-like zinc finger proteins in end-stage COPD lungs with and without severe alpha1-antitrypsin deficiency
19. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
20. Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations
21. Regional differences in prediction models of lung function in Germany
22. Comparison of exhaled breath condensate pH using two commercially available devices in healthy controls, asthma and COPD patients
23. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group, multicentre study
24. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis
25. Künstliche Intelligenz: Was macht gute Medizin aus?
26. Diagnostic Performance of a Machine Learning Algorithm (Asthma/Chronic Obstructive Pulmonary Disease [COPD] Differentiation Classification) Tool Versus Primary Care Physicians and Pulmonologists in Asthma, COPD, and Asthma/COPD Overlap
27. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
28. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
29. Genetic lung diseases
30. Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study
31. Lungenerkrankung nach Senfgasexposition
32. Association of coronary artery calcification with clinical and physiological characteristics in patients with COPD: Results from COSYCONET
33. A scoping review of mHealth monitoring of pediatric bronchial asthma before and during COVID-19 pandemic
34. Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD
35. Quantification of pulmonary perfusion abnormalities using DCE-MRI in COPD: comparison with quantitative CT and pulmonary function
36. Sex-specific associations of comorbidome and pulmorbidome with mortality in chronic obstructive pulmonary disease: results from COSYCONET
37. Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment
38. IgE is associated with exacerbations and lung function decline in COPD
39. Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD ‘real world’ study
40. Cardiovascular predictors of mortality and exacerbations in patients with COPD
41. Bronchodilator Response in Post-COVID-19 Patients Undergoing Pulmonary Rehabilitation.
42. DUPILUMAB IMPROVES RESPIRATORY SYMPTOMS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION: POOLED RESULTS FROM BOREAS AND NOTUS.
43. Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study.
44. Differential Impact of Low Fat-Free Mass in People With COPD Based on BMI Classifications: Results From the COPD and Systemic Consequences-Comorbidities Network
45. Chronisch-obstruktive Lungenerkrankung, schlafbezogene Atemstörungen und Hypoventilation – Einflüsse auf das kardiorenale System
46. Obituary for Prof. Dr. med. Tobias Welte
47. VOC‐based detection of prostate cancer using an electronic nose and ion mobility spectrometry: A novel urine‐based approach
48. Elucidating the risk of cardiopulmonary consequences of an exacerbation of COPD: results of the EXACOS-CV study in Germany
49. Implementing remote monitoring for COVID-19 patients in primary care
50. Early Diagnosis and Treatment of COPD: The Costs and Benefits of Case-Finding
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.